MedTrace Logo

Chloroquine for Glioblastoma.

NCT04772846 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-26

No results posted yet for this study

Summary

Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.

Conditions

Interventions

DRUG

Oral tablet

Oral 250mg chloroquine tablets

DRUG

Placebo

Oral placebo tablets

Sponsors & Collaborators

  • Egyptian Medical Syndicate

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-12-01
Completion
2021-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04772846 on ClinicalTrials.gov